- Home
- PHAT vs PCN Comparison
PHAT vs PCN Comparison
Compare PHAT & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | PCN |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 895.1M |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PHAT | PCN |
|---|---|---|
| Price | $12.70 | $12.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $19.83 | N/A |
| AVG Volume (30 Days) | ★ 969.5K | 427.2K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | N/A |
| Revenue Next Year | $58.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $11.40 |
| 52 Week High | $18.31 | $13.49 |
Technical Indicators
Market Signals| Indicator | PHAT | PCN |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 47.10 |
| Support Level | $12.31 | $11.40 |
| Resistance Level | $12.88 | $12.81 |
| Average True Range (ATR) | 0.63 | 0.14 |
| MACD | 0.26 | 0.05 |
| Stochastic Oscillator | 84.06 | 70.91 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.